Frontiers in Oncology (Dec 2022)

What is the future of treatment de-escalation for HPV-positive oropharyngeal cancer? A review of ongoing clinical trials

  • Emma A. Mensour,
  • Shintha Alam,
  • Seliya Mawani,
  • Houda Bahig,
  • Pencilla Lang,
  • Anthony Nichols,
  • David A. Palma,
  • Katie Jasper

DOI
https://doi.org/10.3389/fonc.2022.1067321
Journal volume & issue
Vol. 12

Abstract

Read online

BackgroundHuman papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has increased in incidence in recent decades. With higher cure rates in younger populations, long-term survivors may live with acute- and long-term toxicity, leading to increased interest in de-escalation treatment strategies for HPV-related OPSCC. Herein, we have examined the current landscape of clinical trials in this context.MethodsA review of active clinical trials related to de-escalation of HPV-associated OPSCC treatment was performed using the clinicaltrials.gov database from inception to January 2022. A search using the key words “oropharyngeal cancer” and “HPV” was completed. Three investigators independently reviewed each trial, with any discrepancies settled by a fourth. Data collected from each study included study phase, study design, primary, and secondary endpoints, and de-escalation treatment strategies. A final 24 articles were selected for full text review.ResultsMany trials (n=19, 79%) were non-randomized, and most studies employed a phase II design (n=14, 58%). Only 13% (n=3) were randomized trials, and 8% (n=2) included a phase III component. The most frequent primary endpoint was progression-free survival (PFS) (n=9, 37.5%). With regards to the identified de-escalation strategies, all the studies (n=24) had at least one component assessing changes in RT dose/fractionation and/or a reduction in RT volumes. A smaller percentage of trials assessed surgical interventions (n=9, 37.5%) and/or changes in systemic therapy (n=8, 33.3%).ConclusionA small number of randomized trials are underway, and a transition to more randomized phase III trials in the future will be important to change clinical practice.

Keywords